Format

Send to

Choose Destination
Rheumatol Int. 2019 Nov 4. doi: 10.1007/s00296-019-04467-6. [Epub ahead of print]

Biologic therapy in the idiopathic inflammatory myopathies.

Author information

1
Central Adelaide Local Health Network, Adelaide, Australia.
2
Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia. vidya.limaye@sa.gov.au.
3
Discipline of Medicine, School of Medicine, University of Adelaide, Adelaide, Australia. vidya.limaye@sa.gov.au.

Abstract

The idiopathic inflammatory myopathies (IIM) are a group of autoimmune diseases resulting from inflammation of muscle and manifesting as weakness, though a range of extra-muscular manifestations are observed. These are often correlated closely with disease subtype and the presence of myositis-specific/myositis-associated antibodies. IIM are notoriously difficult to treat and often refractory to glucocorticoid therapy and synthetic immunosuppressants. Both the innate and adaptive immune systems are implicated in the pathogenesis of IIM. A growing understanding of the key cytokines as well as the cell-mediated and antibody effectors of disease has identified multiple potential targets for biologic therapy. The most widely used of these is B-cell depletion via rituximab though the tumour necrosis factor inhibitors and other biologic therapies used in diseases such as rheumatoid arthritis, systemic lupus erythematosus and multiple sclerosis have also been trialled. This review summarises the literature thus far on biologic therapy in IIM, highlighting both the significant trials that influence current treatment regimens and also the continuing need for further research to inform more effective therapies.

KEYWORDS:

Biologics; Etanercept; Idiopathic inflammatory myopathies; Infliximab; Rituximab

PMID:
31680207
DOI:
10.1007/s00296-019-04467-6

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center